 |
|
|
 |
Events
Every year, there are numerous meetings, conferences, seminars and other events addressing chronic kidney disease. For more information, please visit the Renagel booth while attending these meetings.
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery.
- Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation.
- Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel.
- Patients should be informed to take Renagel with meals and to adhere to their prescribed diets.
Please see accompanying full Prescribing Information.
| |
|
|
|
Genzyme Corporate
